AbbVie has submitted applications for a new indication for upadacitinib (RINVOQ) for the treatment of patients living with ...

AbbVie has submitted applications to the FDA and EMA for new indications for upadacitinib (RINVOQ 15-mg) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV), ...

Studies evaluating the oral JAK inhibitor in adults and adolescents with non-segmental vitiligo are submitted for approval of the expanded indication.

AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ® ...

Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo [1,2] ...

AbbVie on Tuesday said the applications with the U.S. Food and Drug Administration and the European Medicines Agency cover Rinvoq for the treatment of adults and adolescents with non-segmental ...

AbbVie Inc. stays a Strong Buy after a Q4 2025 earnings beat led by HUMIRA, plus growth in immunology and neuroscience. Click ...

AbbVie has submitted regulatory applications in the US and Europe for Rinvoq as a potential first systemic therapy for non segmental vitiligo. The filing seeks to expand Rinvoq's use beyond its ...

Dublin, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's ...

Mamta Mohandas' acting career began with a commercially unsuccessful debut, but she found recognition with 'Big B' and ...